-

Viz.ai Names Jieun Choe Chief Marketing Officer

Industry life sciences veteran to advance growth strategy and execution

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO). Choe will report to CEO Chris Mansi, overseeing global marketing strategy, brand and communications, product marketing and demand generation.

“Jieun’s deep experience and proven track record in driving growth with expert execution will be invaluable as we continue to expand our footprint worldwide,” said CEO Chris Mansi, M.D. “The addition of her customer-centric approach and strategic, growth mindset to our c-suite will help propel Viz.ai into new frontiers.”

Choe was most recently chief strategy and marketing officer at Certara, a global leader in biosimulation, where she headed the global marketing team and drove the strategic planning process. Choe was also instrumental in helping lead the company to a successful IPO in December 2020. Earlier in her career, she worked in product management and strategy at Guidant and Boston Scientific, leading cross-functional teams and driving product strategy and launches.

“I am thrilled to join Viz.ai as it embarks on its next stage of growth,” said Choe. “The company’s purpose-driven, diverse culture is impressive, empowering the Viz team to innovate outstanding solutions to improve patient outcomes and increase access to life-saving care. I look forward to working with the team to accelerate the momentum and fuel growth.”

Choe received her Bachelors of Arts in Public Policy and Economics from Stanford University and a Masters of Business Administration from Stanford University’s Graduate School of Business.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,200+ hospitals and health systems in the US and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, optimizes care pathways and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Joe Duraes
Pazanga Health Communications for Viz.ai
jduraes@pazangahealth.com
+1-917-687-6419

Viz.ai, Inc.


Release Versions

Contacts

Joe Duraes
Pazanga Health Communications for Viz.ai
jduraes@pazangahealth.com
+1-917-687-6419

Social Media Profiles
More News From Viz.ai, Inc.

Viz.ai and Vastrax Join Forces to Accelerate Clinical Trial Enrollment

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO). Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel neurovascular therapies. “Continued development of new technologies in neuro-intervention is the key to bringing better treatment options to patients, and provin...

Viz.ai partners with Illuminate to improve quality of care for aortic aneurysm patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make tim...

New Study Finds 85% of Aneurysms Identified by Viz™ ANEURYSM had not Been Referred for Neurovascular Review

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today shared highlights of new data being presented at the Society of Vascular and Interventional Neuroradiology (SVIN) in Los Angeles next week, demonstrating the significant impact of Viz ANEURYSM at a large hospital system. After screening nearly 1,200 computed tomography angiograms (CTAs) for stroke evaluation across eight stroke centers across Texas with Viz ANEURYSM, a tot...
Back to Newsroom